JP2014534265A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534265A5
JP2014534265A5 JP2014543618A JP2014543618A JP2014534265A5 JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5 JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
amino acid
acid sequence
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014543618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066795 external-priority patent/WO2013082116A1/en
Publication of JP2014534265A publication Critical patent/JP2014534265A/ja
Publication of JP2014534265A5 publication Critical patent/JP2014534265A5/ja
Pending legal-status Critical Current

Links

JP2014543618A 2011-11-28 2012-11-28 インスリンアミノ酸配列を含む治療薬 Pending JP2014534265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563985P 2011-11-28 2011-11-28
US61/563,985 2011-11-28
PCT/US2012/066795 WO2013082116A1 (en) 2011-11-28 2012-11-28 Therapeutic agents comprising insulin amino acid sequences

Publications (2)

Publication Number Publication Date
JP2014534265A JP2014534265A (ja) 2014-12-18
JP2014534265A5 true JP2014534265A5 (enExample) 2016-01-21

Family

ID=48536000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543618A Pending JP2014534265A (ja) 2011-11-28 2012-11-28 インスリンアミノ酸配列を含む治療薬

Country Status (14)

Country Link
US (2) US20130150291A1 (enExample)
EP (1) EP2785367A4 (enExample)
JP (1) JP2014534265A (enExample)
KR (1) KR20140103985A (enExample)
CN (1) CN104080473A (enExample)
AU (1) AU2012346058A1 (enExample)
BR (1) BR112014012789A2 (enExample)
CA (1) CA2856967A1 (enExample)
HK (1) HK1202067A1 (enExample)
IL (1) IL232781A0 (enExample)
MX (1) MX2014006391A (enExample)
RU (1) RU2014126244A (enExample)
SG (1) SG11201402661TA (enExample)
WO (1) WO2013082116A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP2945643A4 (en) * 2013-01-15 2017-04-26 Phasebio Pharmaceuticals, Inc. Therapeutic agents, compositions, and methods for glycemic control
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
WO2015178466A1 (ja) * 2014-05-21 2015-11-26 味の素株式会社 フィブロイン様タンパク質の製造法
JP7075757B2 (ja) * 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ,インコーポレイテッド 制御放出および持続的放出のためのelp融合タンパク質
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
EP3124495A1 (en) * 2015-07-31 2017-02-01 Centre National de la Recherche Scientifique (C.N.R.S.) Derivatives of elastin-like polypeptides and uses thereof
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
CN105061566A (zh) * 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 拟胰岛素多肽及其应用
EP3341405A4 (en) * 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. PROCESS FOR INSULIN PRODUCTION
KR101815080B1 (ko) 2015-11-03 2018-01-04 재단법인대구경북과학기술원 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
EP3448872A4 (en) 2016-04-27 2019-12-11 The Regents of the University of California PREPARATION OF FUNCTIONAL HOMOCYSTEINRESTES IN POLYPEPTIDES AND PEPTIDES
CN118078956A (zh) * 2016-05-06 2024-05-28 免疫新炉有限公司 用于受控和持续释放的elp融合蛋白
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3515928B1 (en) * 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
US11220467B2 (en) 2017-01-11 2022-01-11 Recycle Track Systems, Inc. Indoor food waste fermentation and recycling process
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
CN111939244B (zh) * 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
KR102456958B1 (ko) * 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
EP4071178A4 (en) * 2019-12-06 2024-10-09 Ajinomoto Co., Inc. METHOD FOR PREPARING A PEPTIDE WITH PHYSIOLOGICAL ACTIVITY AND A PEPTIDE WITH A SHORT LINKER
WO2026015937A1 (en) * 2024-07-15 2026-01-22 The University Of Melbourne Novel treatment for diabetes and obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024015A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
JP2009525946A (ja) * 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US8178495B2 (en) * 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
EP1987067A4 (en) * 2006-02-15 2012-01-25 Imclone Llc ANTIBODY FORMULATION
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
WO2010014689A1 (en) * 2008-07-29 2010-02-04 Phasebio Pharmaceuticals, Inc. Pharmaceutical formulations comprising elastin-like proteins
SG178195A1 (en) * 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
JP5801807B2 (ja) * 2009-08-14 2015-10-28 フェーズバイオ ファーマシューティカルズ,インコーポレイテッド 修飾された血管作動性腸管ペプチド

Similar Documents

Publication Publication Date Title
RU2014126244A (ru) Лекарственные средства, содержащие аминокислотные последовательности инсулина
CN102026666B (zh) 促胰岛素肽缀合物制剂
JP2010031018A5 (enExample)
JP6084215B2 (ja) ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
RU2434640C2 (ru) Лечение метастатического рака молочной железы
CA2729938A1 (en) New insulin analogues of prolonged activity
ES2614287T3 (es) Lixisenatida como terapia adicional a la insulina basal en diabetes de tipo 2
JP2021521230A5 (enExample)
ES2932498T3 (es) Composiciones que comprenden el péptido WKDEAGKPLVK
ES2723887T3 (es) Formulación de relación fija de insulina glargina/lixisenatida
MY158627A (en) Halogen-stabilized insulin
WO2012130136A1 (zh) 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
HRP20150353T1 (hr) Farmaceutski pripravak koji sadrži glp-1 agonist, inzulin i metionin
JP2016516076A5 (enExample)
JP2014526441A5 (enExample)
TW200301694A (en) Bicarbonate-based solutions for dialysis therapies
JP2013127002A5 (enExample)
UA95488C2 (ru) Концентрированный раствор метотрексата для подкожного введения
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
ES2971959T3 (es) Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua
JP2017529326A5 (enExample)
CN103665148A (zh) 一种可口服给药的降糖多肽及其制法和用途
JP2014506579A5 (enExample)
JP2020502056A5 (enExample)
ES2743767T3 (es) Agente para prevenir y/o tratar dolor neuropático periférico causado por un fármaco anticancerígeno